文献速递头颈与中枢神经肿瘤

伴与不伴桥本甲状腺炎的甲状腺乳头状癌差异蛋白表达

[Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究收集中国医学科学院肿瘤医院2014—2016年诊治的PTC患者资料,伴HT 103例、不伴HT 109例,用组织芯片和免疫组化检测BRAF、VEGF、cyclin D1、MC、CD56和Galectin3蛋白表达。结果显示两组间BRAF、VEGF、cyclin D1、MC和Galectin3阳性率差异均无统计学意义,而CD56在PTC组织与癌旁甲状腺滤泡上皮间、以及伴与不伴HT的PTC间差异均有统计学意义。

要点

  • BRAF、VEGF、cyclin D1、MC和Galectin3在伴与不伴HT的PTC间表达无显著差异。
  • CD56在PTC组织阳性率27.4%低于癌旁甲状腺滤泡上皮65.0%(P=0.001)。
  • CD56在伴HT的PTC阳性率35.5%高于不伴HT的16.5%(P=0.009)。

核心结论

  • BRAF、VEGF、cyclin D1、MC和Galectin3蛋白在伴有HT的PTC发病机制中未发挥明显特异作用。
  • CD56在伴与不伴HT的PTC间表达差异显著,可能与伴有HT的PTC发生有关。
  • CD56可作为PTC诊断的潜在分子标志物参考指标。

研究设计与样本

  • 收集2014—2016年在中国医学科学院肿瘤医院诊治的PTC患者资料,伴HT患者103例,不伴HT患者109例。
  • 制备组织芯片,采用免疫组化法检测BRAF、VEGF、cyclin D1、MC、CD56和Galectin3蛋白表达水平。

主要发现

  • BRAF蛋白在伴和不伴HT的PTC中阳性表达率分别为55.4%(36/65)和63.6%(42/66),差异无统计学意义(P=0.336)。
  • VEGF蛋白在伴和不伴HT的PTC中阳性表达率分别为25.7%(19/74)和25.8%(17/66),差异无统计学意义(P=0.991)。
  • cyclin D1在伴和不伴HT的PTC中阳性表达率分别为93.4%(71/76)和97.6%(80/82),差异无统计学意义(P=0.206)。
  • MC在伴和不伴HT的PTC中阳性表达率分别为86.1%(62/72)和83.5%(71/85),差异无统计学意义(P=0.654)。
  • Galectin3在伴和不伴HT的PTC中阳性表达率分别为98.7%(76/77)和97.5%(78/80),差异无统计学意义(P=0.583)。

关键数值与推荐

  • CD56在PTC组织和癌旁甲状腺滤泡上皮细胞中阳性表达率分别为27.4%(32/117)和65.0%(76/117),差异有统计学意义(P=0.001)。
  • CD56在伴和不伴HT的PTC中阳性表达率分别为35.5%(24/68)和16.5%(13/79),差异有统计学意义(P=0.009)。

临床怎么用

  • CD56表达检测可作为PTC诊断的参考指标。
  • 对伴HT的PTC患者,CD56低表达模式可能提示与HT相关发病机制,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the differential protein expressions in papillary thyroid carcinoma (PTC) with or without Hashimoto's thyroiditis (HT). Methods: Tissue microarray was prepared and the protein expression levels of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), vascular endothelial growth factor (VEGF), cyclinD1, mesothelial cell (MC) , CD56 and Galectin3 in the PTC tissues with or without HT were detected by immunohistochemical staining. Results: The positive expression rates of BRAF protein in the PTC tissues with or without HT groups were 55.4% (36/65) and 63.6% (42/66), respectively, without significant difference (P=0.336). The positive expression rates of VEGF protein in the PTC tissues with or without HT groups were 25.7% (19/74) and 25.8%(17/66), respectively, without significant difference (P=0.991). The positive expression rates of cyclin D1 protein in the PTC tissues with or without HT groups were 93.4% (71/76) and 97.6% (80/82), without significant difference (P=0.206). The positive expression rates of MC protein in the PTC tissues with or without HT groups were 86.1% (62/72) and 83.5%(71/85), without significant difference (P=0.654). The positive expression rates of Galectin3 protein in the PTC tissues with or without HT groups were 98.7% (76/77) and 97.5% (78/80), without significant difference (P=0.583). The positive expression rates of CD56 in the PTC tissues and adjacent thyroid follicular epithelial cells were 27.4% (32/117) and 65.0% (76/117), respectively, and the difference was statistically significant (P=0.001). The positive expression rates of CD56 in PTC tissues with or without HT were 35.5% (24/68) and 16.5% (13/79), respectively, and the difference was statistically significant (P=0.009). Conclusions: There are no significant differences in the expressions of BRAF, VEGF, CyclinD1, MC and Galectin3 between the PTC tissues with or without HT. However, the significantly differential expression of CD56 between the two group suggests that CD56 may be related to the pathogenesis of PTC with HT. CD56 may be used as a potential molecular marker in PTC diagnosis. 目的: 研究伴和不伴有桥本甲状腺炎(HT)的甲状腺乳头状癌(PTC)的蛋白表达差异。 方法: 收集2014—2016年在中国医学科学院肿瘤医院诊治的PTC患者资料,其中伴HT患者103例,不伴HT患者109例。制备组织芯片,利用免疫组化法检测伴和不伴有HT的PTC中鼠类肉瘤滤过性病毒致癌基因同源体B1(BRAF)、血管内皮细胞生长因子(VEGF)、细胞周期蛋白D1(cyclin D1)、间皮细胞(MC)、CD56和半乳糖凝集素3(Galectin3)蛋白的表达水平,分析蛋白表达差异。 结果: BRAF蛋白在伴和不伴HT的PTC中的阳性表达率分别为55.4%(36/65)和63.6%(42/66),差异无统计学意义(P=0.336)。VEGF蛋白在伴和不伴HT的PTC中的阳性表达率分别为25.7%(19/74)和25.8%(17/66),差异无统计学意义(P=0.991)。cyclin D1在伴和不伴HT的PTC中的阳性表达率分别为93.4%(71/76)和97.6%(80/82),差异无统计学意义(P=0.206)。MC在伴和不伴HT的PTC中的阳性表达率分别为86.1%(62/72)和83.5%(71/85,),差异无统计学意义(P=0.654)。Galectin3在伴和不伴HT的PTC中的阳性表达率分别为98.7%(76/77)和97.5%(78/80),差异无统计学意义(P=0.583)。CD56在PTC组织和癌旁甲状腺滤泡上皮细胞中的阳性表达率分别为27.4%(32/117)和65.0%(76/117),差异有统计学意义(P=0.001);在伴和不伴HT的PTC中的阳性表达率分别为35.5%(24/68)和16.5%(13/79),差异有统计学意义(P=0.009)。 结论: BRAF、VEGF、cyclin D1、MC和Galectin3蛋白在伴有HT的PTC的发病机制中未发挥明显特异作用;CD56的表达情况可以作为PTC诊断的参考指标;CD56可能与伴有HT的PTC的发生有关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu HZ, Zhang N, Liu W, et al. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32575941. doi:10.3760/cma.j.cn112152-20191219-00824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。